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Abstract
Background: Racial disparities in survival of patients with cancer motivate research to quantify treatment disparities and
evaluate multilevel determinants. Previous research has not evaluated cardiac radiation dose in large cohorts of breast
cancer patients by race nor examined potential causes or implications of dose disparities. Methods: We used a statewide
consortium database to consecutively sample 8750 women who received whole breast radiotherapy between 2012 and 2018.
We generated laterality- and fractionation-specific models of mean heart dose. We generated patient- and facility-level models to estimate race-specific cardiac doses. We incorporated our data into models to estimate disparities in ischemic cardiac
event development and death. All statistical tests were 2-sided. Results: Black and Asian race independently predicted higher
mean heart dose for most laterality-fractionation groups, with disparities of up to 0.42 Gy for Black women and 0.32 Gy for
Asian women (left-sided disease and conventional fractionation: 2.13 Gy for Black women vs 1.71 Gy for White women,
P < .001, 2-sided; left-sided disease and accelerated fractionation: 1.59 Gy for Asian women vs 1.27 Gy for White women,
P ¼ .002). Patient clustering within facilities explained 22%-30% of the variability in heart dose. The cardiac dose disparities
translated to estimated excesses of up to 2.6 cardiac events and 1.3 deaths per 1000 Black women and 0.7 cardiac events and
0.3 deaths per 1000 Asian women vs White women. Conclusions: Depending on laterality and fractionation, Asian women
and Black women experience higher cardiac doses than White women. This may translate into excess radiation-associated
ischemic cardiac events and deaths. Solutions include addressing inequities in baseline cardiac risk factors and facility-level
availability and use of radiation technologies.

Whole breast radiotherapy (RT) increases the risk of ischemic
cardiac events (1), with incidence and mortality risk further increased by baseline cardiac risk factors. This underscores the
importance of minimizing cardiac dose among women with
breast cancer. Dose-reducing strategies exist, including early diagnosis (reduced need for internal mammary nodal treatment)
and cardiac dose-reducing radiation techniques (2). If applied
consistently, these strategies can minimize cardiac dose for all
patients. If applied inconsistently, however, cardiac dose may
be unnecessarily elevated among specific demographic subgroups. Disparities in cardiac dose may be particularly harmful

for racial and ethnically minoritized women, given the increased prevalence of cardiac risk factors (3).
Despite the importance of reducing cardiac dose, studies
show statistically significant patient-level variation in cardiac
dose (4). Research is needed to understand and correct factors
causing unwarranted variation in cardiac dose and investigate
whether racial disparities exist. Factors that mediate cardiac
dose (4) may be unevenly distributed between racial and ethnic
subpopulations. Although some mediators may be nonmodifiable (eg, year of diagnosis), multilevel, modifiable mediators
may exist across the cancer continuum. Prediagnosis mediators
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Methods
Data Collection and Sampling

ARTICLE

The Michigan Radiation Oncology Quality Consortium (MROQC)
is a state-wide collaborative designed to improve patients’
experiences with RT (4). Deidentified patient-level clinical and
radiation data are collected in a centralized database (6). This
study was considered institutional review board exempt due to
quality assurance status.
We queried the MROQC database for RT dosimetry to examine racial differences in mean heart dose (MHD) among women
treated with whole breast RT at 25 institutions between January
1, 2012, or January 1, 2014 (heart dose collection began earlier in
left- vs right-sided plans) and August 31, 2018. Given that MHD
is dependent on disease laterality and fractionation, we generated separate models based on disease laterality (right vs left)
and receipt of conventional (CWBI) vs accelerated whole breast
irradiation (AWBI).
Race was self-reported (71.0%) and, if missing, was extracted
from the hospital’s electronic medical record (29.0%). Given the
missingness (34.4%) and low prevalence of Hispanic, Latina, and
Latinx ethnicity, we omitted ethnicity from the analysis. For the
final analysis, we included Asian, Black, and White racial groups
and removed others (American Indian or Alaska Native, Native
Hawaiian or other Pacific Islander, and Arab or Middle Eastern
groups, unknown or not reported and other, please specify, 3.6%
of the sample).

Statistical Analysis
Given that MHD is a skewed (nonnormal) distribution, we used
linear regression but modeled the MHD natural logarithm. We
estimated average MHD by centering age at 60 years, year in
2015, minimum dose covering 50% of the breast (D50) at 48 Gy
(mean), continuous covariates at or near their mean or median
value, and other categorical values as appropriate to facilitate
interpretation.
We generated 6 sequential patient- or multilevel models for
each subpopulation based on the phase of the cancer continuum (covariates shown in Table 2 and the Supplementary
Methods and Tables; available online): 1) nonmodifiable, 2) prediagnosis, 3) cancer workup and pre-RT treatment, 4) radiation

oncology, 5) clustering within facilities, and 6) facility type. P
values less than .05 were considered statistically significant (2sided). To quantify the amount of variability in MHD attributable to facility differences in practice, we calculated intraclass
correlational and variance partitioning coefficients.
To quantify the clinical significance of disparities in cardiac
dose, we applied our dosimetric data to existing models (1) to
quantify differences in cumulative risk (by age 80 years) of 1) development of at least 1 radiation-related acute coronary event
and 2) radiation-related death from ischemic cardiac disease.
Details for our method to quantify cumulative risk are presented in the Supplementary Methods (available online).
Statistics were performed using the SAS System version 9.4
(Cary, NC, USA).

Results
Table 1 shows the characteristics of the 8750 women treated
with whole breast radiotherapy between 2012 and 2018. The final sample was comprised of 1.9% Asian women, 18.3% Black
women, and 79.9% White women. Black women (63.5%) and
Asian women (62.4%) were more likely to be treated at academic
institutions than White women (29.4%). Asian women were
younger (mean age 54.9 years vs 60.8 years for Black women
and 61.9 years for White women). Black women had larger
mean breast and lumpectomy bed volumes, were less likely to
be treated using DIBH, 3-dimensional conformal radiotherapy
(vs IMRT), and AWBI, and were more likely to have triple negative disease, obesity, and at least 1 cardiac risk factor (Black
women ¼ 89.1%; Asian women ¼ 43.0%; White women ¼ 69.6%).

Left-Sided Conventional Fractionation
Regression results by race are shown in Table 2, with the complete list of covariates shown in Supplementary Table 3 (available online). The estimated MHD for the baseline for White
women was approximately 1.7-1.8 Gy for all models. In Model 1,
which included race, age, year, and triple-negative disease,
heart dose was statistically significantly higher for Black
women (24.5%, 95% CI ¼ 19.9% to 29.2%, P < .001) but not Asian
women (2.7%, 95% CI ¼ 16.5% to 11.1%). For Black women,
controlling for prediagnosis (body mass index, breast volume,
comorbidities, smoking) and workup or pre-RT treatment (disease stage, chemotherapy or trastuzumab) had minimal influence on the disparity (Model 2: 23.5%, 95% CI ¼ 18.8% to 28.3%
and Model 3: 22.5%, 95% CI ¼ 17.8% to 27.2%). Controlling for radiation technique (breast D50, DIBH use, IMRT use, positioning,
nodal treatment, and boost use) reduced cardiac dose (Model 4:
15.5%, 95% CI ¼ 11.0% to 19.9%, P < .001). Controlling for clustering within facilities further reduced dose (Model 5: 8.3%, 95% CI
¼ 3.5% to 13.1%, P < .001), but further controlling for academic or
teaching status had minimal impact (Model 6: 8.3%, 95% CI ¼
3.5% to 13.1%, P < .001). Estimates for Asian women changed
minimally across models.

Left-Sided Accelerated Fractionation
The estimated MHD for the baseline White women increased
from 1.27 in Model 1 to 1.56 in Model 5. In Model 1, heart dose
was statistically significantly higher for Black women (20.1%,
95% CI ¼ 14.9% to 25.3%, P < .001) and Asian women (24.9%, 95%
CI ¼ 8.9% to 40.3%, P < .001) (details shown in Supplementary
Table 3, available online). Controlling for societal factors,
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such as body mass index, breast volume, and comorbidities are
considered modifiable because they are influenced by forces
like structural racism (5) that drive disparities in social determinants of health. Cancer workup and treatment mediators,
which can also be modifiable, include disease stage and use of
cardiotoxic systemic therapies. Radiation technique mediators
include deep inspiration breath hold (DIBH) use and other RT
technical delivery factors [eg, 3-dimensional vs intensity modulated radiation therapy (IMRT) (4) use]. Cardiac dose may also be
mediated through institutional practices attributable to treatment facility. This may be evident by examining factors like the
type of practice (academic or community) of the facility or observing attenuation of the disparity when accounting for institution common practice by clustering patients within treating
facilities.
We therefore used a statewide consortium to explore racial
differences in cardiac dose. Our findings are designed to inform
multilevel strategies to mitigate disparities in cardiac event risk
among women with breast cancer.
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Table 1. Sample characteristics, all patients, stratified by race

Lumpectomy bed total
volume
Total No.
Mean (SD), cc
Median [IQR], cc
Smoking status, No. (%)
Never smoker
Former smoker
Current smoker
Comorbidities count categories, No. (%)
Not reported
0
1
2
3þ

Asian women

Black women

White women

315 (3.6)
556 (6.4)
1517 (17.3)
1852 (21.2)
1945 (22.2)
1720 (19.7)
845 (9.7)

4 (2.4)
11 (6.7)
27 (16.4)
29 (17.6)
34 (20.6)
32 (19.4)
28 (17.0)

67 (4.2)
107 (6.7)
313 (19.6)
335 (20.9)
325 (20.3)
314 (19.6)
139 (8.7)

244 (3.5)
438 (6.3)
1177 (16.9)
1488 (21.3)
1586 (22.7)
1374 (19.7)
678 (9.7)

.05

.10

<.001

<.001

5576 (63.7)
3174 (36.3)

62 (37.6)
103 (62.4)

584 (36.5)
1016 (63.5)

4930 (70.6)
2055 (29.4)

8750
61.6 (10.8)
61.8 [53.9-69.1]

165
54.9 (10.7)
52.4 [46.4-63.9]

1600
60.8 (11.2)
60.8 [53.0-68.5]

6985
61.9 (10.6)
62.2 [54.3-69.4]

1310 (15.0)
2539 (29.0)
2921 (33.4)
1980 (22.6)

59 (35.8)
56 (33.9)
35 (21.2)
15 (9.1)

281 (17.6)
457 (28.6)
527 (32.9)
335 (20.9)

970 (13.9)
2026 (29.0)
2359 (33.8)
1630 (23.3)

8731
80.5 (19.1)
77.8 [66.6-90.9]

164
62.0 (10.2)
59.4 [54.4-69.4]

1598
86.9 (19.9)
84.5 [73.4-97.5]

6969
79.5 (18.6)
76.7 [65.8-89.8]

<.001
<.001

8653
30.3 (7.0)
29.3 [25.2-34.3]

163
24.8 (4.0)
24.4 [21.8-27.5]

1593
32.6 (7.2)
31.8 [27.8-36.5]

6897
30.0 (6.9)
28.8 [24.9-33.8]

<.001
<.001

156 (1.8)
2016 (23.0)
2609 (29.8)

9 (5.5)
84 (50.9)
52 (31.5)

13 (0.8)
198 (12.4)
417 (26.1)

134 (1.9)
1734 (24.8)
2140 (30.6)

2020 (23.1)
1110 (12.7)
839 (9.6)

20 (12.1)
0(0)
0(0)

452 (28.3)
298 (18.6)
222 (13.9)

1548 (22.2)
812 (11.6)
617 (8.8)

8724
1143.3 (643.5)
1023.4 [685.81471.7]

165
710.8 (375.2)
627.4 [446.4-896.8]

1596
1359.5 (774.8)
1219.3 [814.81736.5]

6963
1104.1 (601.0)
993.4 [675.01419.6]

8491
41.5 (71.5)
22.7 [11.5-46.1]

158
28.1 (32.1)
18.3 [9.2-34.5]

1564
67.5 (98.9)
34.2 [14.4-81.2]

6769
35.8 (62.8)
21.3 [11.1-41.4]

4988 (57.0)
2767 (31.6)
995 (11.4)

144 (87.3)
14 (8.5)
7 (4.2)

858 (53.6)
499 (31.2)
243 (15.2)

3986 (57.1)
2254 (32.3)
745 (10.7)

<.001
.001
<.001

<.001

3 (0.0)
3708 (42.4)
2948 (33.7)
1492 (17.1)
599 (6.8)

0(0)
101 (61.2)
39 (23.6)
23 (13.9)
2 (1.2)

1 (0.1)
380 (23.8)
588 (36.8)
435 (27.2)
196 (12.3)

<.001

<.001

ARTICLE

Year of radiotherapy completion, No. (%)
2012
2013
2014
2015
2016
2017
2018
Academic (teaching) treating institution, No. (%)
No
Yes
Age
Total No.
Mean (SD), y
Median [IQR], y
Age groups, No. (%)
<50 y
50 to <60 y
60 to <70 y
70þ y
Weight
Total No.
Mean (SD), kg
Median [IQR], kg
BMI
Total No.
Mean (SD), kg/m2
Median [IQR], kg/m2
BMI categories, No. (%)
Underweight <18.5 kg/m2
Normal 18.5 to <25 kg/m2
Overweight 25 to
<30 kg/m2
Obesity I 30 to <35 kg/m2
Obesity II 35 to <40 kg/m2
Obesity III >40 kg/m2
Breast total volume
Total No.
Mean (SD), cc
Median [IQR], cc

All patients
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Variable

Pa for White Pa for White Pb continuvs Black
vs Asian
ous
women
women
variables

<.001
<.001

<.001
<.001
<.001

<.001

<.001

<.001

2 (0.0)
3227 (46.2)
2321 (33.2)
1034 (14.8)
401 (5.7)
(continued)
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Table 1. (continued)

ARTICLE

Hypertension, No. (%)
Not reported
No
Yes
Diabetes, No. (%)
Not reported
No
Yes
Cardiac risk factor, No. (%)
No
Yes
AJCC 7th ed. Stage of
Disease, No. (%)
Not reported
0
1
2
3
Final surgical margins,
No. (%)
Not reported
Close
Negative
Positive
Triple-negative disease, No.
(%)
Not reported
No
Yes
Chemotherapy (excluding
trastuzumab), No. (%)
Not reported
No
Yes
Trastuzumab, No. (%)
Not reported
No
Yes
Hormone therapy, No. (%)
Not reported
No
Yes
IMRT, No. (%)
No
Yes
Delivery type/fractionation,
No. (%)
3DRT/CWBI
3DRT/AWBI
IMRT/CWBI
IMRT/AWBI
Deep inspiration breath
hold, No. (%)
No
Yes
Nodal radiotherapy treatment, No. (%)
Without nodal trt or
Axillary (I/II) only

All patients

Asian women

Black women

White women

3 (0.0)
4619 (52.8)
4128 (47.2)

0(0)
115 (69.7)
50 (30.3)

1 (0.1)
504 (31.5)
1095 (68.4)

2 (0.0)
4000 (57.3)
2983 (42.7)

3 (0.0)
7366 (84.2)
1381 (15.8)

0(0)
140 (84.8)
25 (15.2)

1 (0.1)
1168 (73.0)
431 (26.9)

2 (0.0)
6058 (86.7)
925 (13.2)

2394 (27.4)
6356 (72.6)

94 (57.0)
71 (43.0)

175 (10.9)
1425 (89.1)

2125 (30.4)
4860 (69.6)

38 (0.4)
1722 (19.7)
4429 (50.6)
2311 (26.4)
250 (2.9)

137 (1.6)
1182 (13.5)
7143 (81.6)
288 (3.3)

22 (0.3)
7885 (90.1)
843 (9.6)

0(0)
34 (20.6)
79 (47.9)
48 (29.1)
4 (2.4)

7 (4.2)
20 (12.1)
130 (78.8)
8 (4.8)

1 (0.6)
146 (88.5)
18 (10.9)

8 (0.5)
378 (23.6)
682 (42.6)
473 (29.6)
59 (3.7)

20 (1.3)
215 (13.4)
1318 (82.4)
47 (2.9)

3 (0.2)
1326 (82.9)
271 (16.9)

33 (0.5)
4965 (71.1)
1987 (28.4)

35 (0.4)
7910 (90.4)
805 (9.2)

0(0)
145 (87.9)
20 (12.1)

2 (0.1)
1422 (88.9)
176 (11.0)

33 (0.5)
6343 (90.8)
609 (8.7)

1968 (22.5)
2295 (26.2)
4487 (51.3)

44 (26.7)
49 (29.7)
72 (43.6)

336 (21.0)
454 (28.4)
810 (50.6)

1588 (22.7)
1792 (25.7)
3605 (51.6)

4625 (52.9)
4125 (47.1)

106 (64.2)
59 (35.8)

478 (29.9)
1122 (70.1)

4041 (57.9)
2944 (42.1)

7383 (84.4)
1367 (15.6)

133 (80.6)
32 (19.4)

1475 (92.2)
125 (7.8)

<.001

<.001

<.001

<.001

.63

.69

.49

<.001

.16

<.001

.002

.005

.13

.07

.09

<.001

.10

<.001

.16

<.001

.49

<.001

.01

18 (0.3)
6413 (91.8)
554 (7.9)

2 (0.1)
988 (61.8)
610 (38.1)

305 (19.1)
173 (10.8)
632 (39.5)
490 (30.6)

<.001

110 (1.6)
947 (13.6)
5695 (81.5)
233 (3.3)

0(0)
100 (60.6)
65 (39.4)

58 (35.2)
48 (29.1)
33 (20.0)
26 (15.8)

<.001

30 (0.4)
1310 (18.8)
3668 (52.5)
1790 (25.6)
187 (2.7)

35 (0.4)
6053 (69.2)
2662 (30.4)

2336 (26.7)
2289 (26.2)
2110 (24.1)
2015 (23.0)

<.001

1973 (28.2)
2068 (29.6)
1445 (20.7)
1499 (21.5)

5775 (82.7)
1210 (17.3)

7730 (88.3)

137 (83.0)

1356 (84.8)

6237 (89.3)

587 (6.7)

12 (7.3)

171 (10.7)

404 (5.8)
(continued)
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Variable

Pa for White Pa for White Pb continuvs Black
vs Asian
ous
women
women
variables
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Table 1. (continued)

Asian women

Black women

White women

433 (4.9)

16 (9.7)

73 (4.6)

344 (4.9)

1556 (17.8)
7194 (82.2)

21 (12.7)
144 (87.3)

167 (10.4)
1433 (89.6)

1368 (19.6)
5617 (80.4)

595 (6.8)
8155 (93.2)

3 (1.8)
162 (98.2)

181 (11.3)
1419 (88.7)

411 (5.9)
6574 (94.1)

8624
48.2 (4.4)
47.2 [44.4-51.9]

165
48.1 (4.3)
47.3 [44.5-51.4]

1578
49.5 (4.9)
48.6 [45.3-52.5]

6881
47.9 (4.3)
46.9 [44.2-51.7]

<.001

.03

<.001

.03

<.001
.38

a

P values for the comparison of White with Black women and White with Asian women using the v2 test statistic for categorical data. 3DCRT ¼ 3-dimensional confor-

mal radiotherapy; AWBI ¼ accelerated whole breast irradiation; BMI ¼ body mass index; CWBI ¼ conventionally fractionated whole breast irradiation; ICV ¼ infraclavicular; IMRT ¼ intensity modulated radiation therapy; IQR ¼ interquartile range; SCV ¼ supraclavicular; trt ¼ treatment; w/ ¼ with; w/o ¼ without.
b

t test statistic for continuous data.

health-care system, staging, and workup factors, and radiation
technique factors had minimal influence on these disparities.
Controlling for clustering within facilities further reduced the
estimated mean cardiac dose modestly for Asian women (Model
4: 23.6% vs Model 5: 15.5%, 95% CI ¼ 2.6% to 28.5%, P ¼ .008) and
substantially for Black women (Model 4: 17.2%, Model 5: 6.9%,
95% CI ¼ 1.4% to 12.4%, P ¼ .01). Further controlling for academic
or community status had minimal impact.

Variance Partitioning for Facility-Level Contribution
The intraclass correlation ranged from 25.5% for right-sided
CWBI to 29.2% for right-sided ABWI, with left-sided intraclass
correlations of 26.7% for both fractionation types. The variance
partitioning coefficients for the full models (Model 6) ranged
from 23.1% for right-sided CWBI to 31.9% for left-sided CWBI.
Accounting for covariates reduced the residual variance by
larger amounts for the left-sided models than for right-sided
models (Table 3).

Right-Sided Conventional Fractionation
The estimated MHD for the baseline White women was approximately 0.67 Gy for all models. There were no racial disparities
across Models 1 through 6 for any racial group.

Right-Sided Accelerated Fractionation
The estimated MHD for the baseline White women was approximately 0.60 Gy for all models. In Model 1, heart dose was statistically significantly higher for Asian women (14.4%, 95% CI ¼
0.4% to 28.4%, P ¼ .04) and Black women (6.8%, 95% CI ¼ 1.4% to
12.2%, P ¼ .01). Across all 6 models, heart dose was higher for
Black women vs White women (P < .049). There was no trend
across the models for Asian women or Black women (Asian
women: Models 1–6, range ¼ 9.7%-14.4%; Black women: Models
1–6, range ¼ 5.6%-12.4%).

Mediators of Cardiac Dose
In the final models (Model 6), the following factors were predictors for higher heart dose regardless of laterality or fractionation: supine positioning, earlier year of diagnosis, higher
breast volume, IMRT, and breast D50. For conventional fractionation, lack of DIBH and nodal RT (both IMN and supraclavicular
or infraclavicular without IMNs) were associated with higher
cardiac dose. Other factors were statistically significantly associated with elevated cardiac dose depending on the model.

Unexplained Disparity
For Black women with left-sided disease, one-third (33.7%33.9%) of the disparity remained unexplained in Model 6. For
Asian women, the covariates explained little of the disparity,
with 55.6%-78.4% of the Model 1 disparity remained unexplained in Model 6.

Estimated Impact on Cardiac Events
Figure 1A shows Model 1 cardiac doses by race for left-sided
conventionally fractionated RT (Asian women ¼ 1.66 Gy, Black
women ¼ 2.13 Gy, White women ¼ 1.71 Gy). Accounting for all
mediators included in Models 2-6 reduced heart dose among
Black women to 1.92 Gy (vs 1.77 Gy for White women) and had
minimal change for Asian women. Figure 1B shows Model 1 cardiac doses by race for left-sided AWBI (Asian women ¼ 1.59 Gy,
Black women ¼ 1.53 Gy, White women ¼ 1.27 Gy). Accounting
for all mediators included in Models 2-6 reduced disparities in
heart dose among Asian women and Black women (1.79 Gy and
1.66 Gy, respectively, vs 1.55 Gy for White women).
Using data from Darby et al. (1), we estimated that the disparity (after accounting for only nonmodifiable covariates,
Model 1) currently experienced by Black women undergoing
CWBI for left-sided disease results in an excess of 2.6 ischemic
cardiac events and 1.3 cardiac deaths by age 80 years per 1000
women (Figure 2, events: Asian women ¼ 6.12, Black women ¼

ARTICLE

Supra or infraclavicular
nodal treatment
Internal mammary
trt w/or w/o SCV/IVC trt
Boost to lumpectomy bed,
No. (%)
No
Yes
Treatment position, No. (%)
Prone
Supine
D50 to the Breast
Total No.
Mean (SD)
Median [IQR]

All patients
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Variable

Pa for White Pa for White Pb continuvs Black
vs Asian
ous
women
women
variables

ARTICLE
Model 1 (age, tx year, triplenegative status)
Laterality and fractionation/intercept
and race
Left-sided
conventional
Intercept (baseline
estimate), Gy
Race group
Asian, %

a
b

Model 4 (Model 3 þ breast D50,
DIBH, nodal radiotherapy,
IMRT use, prone positioning, Model 5 (Model 4 þ clustering
boost use)
within facilities)

Model 6 (Model 5 þ academic/
teaching status)

Mean heart dose
(95% CI)

Pa

Mean heart dose
(95% CI)

Pa

Mean heart dose
(95% CI)

Pa

Mean heart dose
(95% CI)

Pa

Mean heart dose
(95% CI)

Pa

Mean heart dose
(95% CI)

Pa

1.71 (1.67 to 1.75)

<.001

1.81 (1.70 to 1.92)

<.001

1.71 (1.60 to 1.83)

<.001

1.66 (1.55 to 1.77)

<.001

1.79 (1.57 to 2.04)

<.001

1.77 (1.53 to 2.05)

<.001

.70

1.5 (15.26 to
12.33)
23.5 (18.79 to 28.26)

2.7 (16.54 to
11.14)
Black, %
24.5 (19.90 to 29.16)
White (referent)
Left-sided accelerated
Intercept (baseline
1.27 (1.24 to 1.30)
estimate), Gy
Race group
Asian to %
24.9 (8.94 to 40.81)
Black to %
20.1 (14.89 to 25.27)
White (referent)
Right-sided
conventional
Intercept (baseline
0.69 (0.67 to 0.71)
estimate) to Gy
Race group
Asian to %
3.6 (11.12 to 18.32)
Black to %
White (referent)
Right-sided
accelerated
Intercept (baseline
estimate)
Race group
Asian to %
Black to %
White (referent)

Model 2 (Model 1 þ BMI, breast Model 3 (Model 2 þ disease
volume, comorbidities, smok- stage, chemotherapy receipt,
ing status)
trastuzumab receipt)

<.001
<.001b

0.84

0.0 (13.67 to 13.58)

0.99

1.2 (11.27 to 13.73)

0.85

2.8 (8.65 to 14.21)

.63

2.8 (8.67 to 14.19)

.64

<.001
<.001b

22.5 (17.82 to 27.22)

<.001
<.001b

15.5 (11.03 to 19.91)

<.001
<.001b

8.3 (3.51 to 13.13)

<.001
.003b

8.3 (3.45 to 13.08)

<.001
.003b

<.001

1.33 (1.25 to 1.41)

<.001

1.33 (1.25 to 1.42)

<.001

1.50 (1.40 to 1.60)

<.001

1.56 (1.39 to 1.76)

<.001

1.55 (1.35 to 1.77)

<.001

.002
<.001
<.001b

24.4 (8.58 to 40.29)
20.0 (14.70 to 25.27)

.003
<.001
<.001b

24.1 (8.30 to 39.98)
20.3 (14.96 to 25.58)

.003
<.001
<.001b

23.6 (8.93 to 38.22)
17.2 (11.98 to 22.39)

.002
<.001
<.001b

15.5 (2.59 to 28.48)
6.9 (1.38 to 12.41)

.02
.01
.004b

15.5 (2.55 to 28.44)
6.8 (1.28 to 12.34)

.02
.02
.004b

<.001

0.72 (0.67 to 0.78)

<.001

0.66 (0.61 to 0.72)

<.001

0.64 (0.59 to 0.69)

<.001

0.66 (0.58 to 0.75)

<.001

0.66 (0.57 to 0.76)

<.001

5.0 (17.81 to
7.92)
5.6 (0.29 to 11.43)

.63

4.0 (10.94 to 18.95)

.60

2.0 (12.58 to 16.66)

.78

2.3 (11.53 to 16.20)

.74

4.7 (0.74 to 10.14)

.09
.23b

5.2 (0.51 to 10.83)

.07
.19b

4.5 (1.12 to 10.10)

.12
.29b

3.3 (2.14 to 8.73)

.23
.48b

0.56 (0.54 to 0.58)

<.001

0.60 (0.56 to 0.64)

<.001

0.60 (0.56 to 0.64)

<.001

0.62 (0.58 to 0.67)

<.001

14.4 (0.44 to 28.39)
6.8 (1.37 to 12.24)

.04
.01
.009b

13.8 (0.32 to 27.97)
8.0 (2.36 to 13.56)

.06
.005
.004b

13.9 (0.26 to 28.04)
7.8 (2.20 to 13.46)

.05
.006
.005b

9.7 (3.92 to 23.25)
5.6 (0.03 to 11.25)

.16
.049
.06b

Linear regression to 2-sided P values. BMI ¼ body mass index; DIBH ¼ deep inspiration breath hold; IMRT ¼ intensity modulated radiation therapy.

Group P values. Linear regression to 2-sided P values.

.45

5.0 (17.86 to 7.88)

.45

.06
.12b

5.5 (0.35 to 11.40)

.07
.12b

0.62 (0.54 to 0.70)

<.001

0.60 (0.52 to 0.69)

<.001

11.4 (0.26 to 23.08)
12.4 (6.84 to 17.87)

.06
<.001
<.001b

11.3 (0.37 to 22.97)
12.2 (6.72 to 17.76)

.06
<.001
<.001b
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Table 2. Single and multilevel models explaining mean heart dose
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Table 3. Variance attributable to patients being clustered by treatment facilitiesa
VPC for full model
(Model 6) to %

Percent reduction in residual
variance (full to empty) to %

26.7
26.7
25.5
29.2

31.9
29.4
23.1
30.4

19.3
21.4
15.6
10.2

a

AWBI ¼ accelerated whole breast irradiation; CWBI ¼ conventionally fractionated whole breast irradiation; ICC ¼ intraclass correlation; VPC ¼ variance portioning

coefficient.

Figure 1. Mean heart dose by race for women with left-sided disease undergoing conventionally fractioned (A) and accelerated (B) whole breast radiotherapy. Six separate models control for modifiable individual- and facility-level mediators of cardiac dose. For conventionally fractionated whole breast radiotherapy, doses for Black
women are elevated compared with those of Asian women and White women. This disparity decreases as radiotherapy (RT) technique and clustering for facilities are
controlled for. For accelerated whole breast radiotherapy, doses for Asian and Black women are elevated compared with those of White women. Clustering within facilities accounts for a substantial proportion of the disparity among Black women but only a modest proportion for Asian women. Error bars represent 95% confidence
intervals. Tx ¼ treatment.

9.52, White women ¼ 6.91; deaths: Asian women ¼ 3.06, Black
women ¼ 4.76, White women ¼ 3.46). For Asian women undergoing CWBI for left-sided disease, the combination of similar
MHD but lower prevalence of cardiac risk factors resulted in
estimates of 0.8 fewer cardiac events and 0.4 deaths per 1000
Asian women vs White women (Figure 2). For women with leftsided disease treated with AWBI, we estimate an excess of 1.7
events and 0.8 death per 1000 Black women and 0.7 events and
0.4 deaths per 1000 women for Asian women vs White women
(Figure 2 events: Asian women ¼ 5.83, Black women ¼ 6.82,
White women ¼ 5.13; deaths: Asian women ¼ 2.92, Black
women ¼ 3.41, White women ¼ 2.57).

Discussion
In this study of cardiac dose among women undergoing whole
breast RT, we identified statistically and clinically significant racial disparities. To our knowledge, this the first study examining
racial disparities in cardiac dose across institutions. After accounting for nonmodifiable factors, cardiac dose was 7%-25%
higher among Asian women and Black women treated with

accelerated fractionation (regardless of laterality) and 25%
higher among Black women with left sided-disease treated with
conventional fractionation. The largest mediators were facilitylevel variation in practice and individual-level differences in radiation technique. However, disparities were not fully
explained, especially for Asian women. When accounting for
disparities in baseline cardiac risk factors, the dosimetric disparities translated into an estimated excess of 2.6 ischemic
events and 1.3 deaths per 1000 Black women treated with conventional fractionation for left-sided disease compared with
White women. Smaller, but notable disparities occurred for
Asian women and Black women treated with accelerated fractionation for left-sided disease. These disparities should be
addressed.
DIBH use may partially explain these disparities. DIBH
reduces dose in up to 67% of women (7-10). In our study, controlling for radiation technique, which included DIBH, reduced
the dose disparity for Black women by 30%. DIBH was only used
in 14% of Black women vs approximately 30%-45% of Asian
women and White women treated with conventional fractionation for left-sided disease. Patient tolerance (11) drives DIBH
use (due to the required breath hold) but is unlikely the sole

ARTICLE

Left-sided CWBI
Left-sided AWBI
Right-sided CWBI
Right-sided AWBI

ICC (empty model (ie
no covariates only clustering)) to %

Downloaded from https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac120/6653306 by Henry Ford Hospital - Sladen Library user on 29 September 2022

Population

8 | JNCI J Natl Cancer Inst, 2022, Vol. 00, No. 0

ated whole breast irradiation at age 60 years for left-sided disease. This figure shows race-stratified estimates for the number of women experiencing at least 1 radiation-associated ischemic cardiac event or death from an ischemic cardiac event by age 80 years as a result of radiation received at age 60 years. Mean cardiac doses
were derived from Model 1, given that these doses most closely reflect the present-day experience. Absolute risks were calculated using the prevalence of 0 vs 1 or
more cardiac risk factors.

ARTICLE

explanation. Instead, facility availability and/or typical practice
may drive DIBH use, because it was not used during the study
period at the 2 facilities with the largest proportions of Black
women (where 50% of Black women were treated). DIBH is reportedly affordable to most departments (12-14), but inequities
in payor mix across facilities may drive disparities. This illustrates how structural racism can drive facility-level disparities.
Additional radiation factors beyond DIBH may drive cardiac
dose disparities. IMRT was used more commonly in Black women
and associated with increased cardiac dose in this and previous
MROQC studies (4). Although some IMRT techniques may decrease cardiac dose relative to tangents, others may increase cardiac dose (15) (eg, previous analyses suggested higher MHD with
inverse vs forward planning) (4). It is unknown whether IMRT
techniques inadvertently increased cardiac dose and mediated
the observed racial disparities. Optimal IMRT techniques may be
inadvertently underused in Black women, given the literature
demonstrating racial disparities in technology dissemination (1620). However, independent of a causal mechanism, IMRT may
simply represent a marker for “unfavorable” anatomy.
Physicians may employ IMRT for unfavorable anatomy (extreme
anterolateral cardiac location). Even if IMRT is optimized to reduce dose compared with standard tangents, the average dose
may exceed that of patients with “favorable” anatomy in whom
3-dimensional techniques are often employed. Future studies
should conduct more sophisticated dosimetric analyses and collect data that could illuminate the rationale for IMRT use, because distinguishing between use for unfavorable heart position
vs standard treatment would help clarify whether IMRT is contributing to cardiac dose disparities. Further research is needed
to optimize IMRT tradeoffs, because minimization of cardiac
dose can increase breast dose heterogeneity and noncardiac toxicity or lead to tumor bed undercoverage.
We also found that cardiac dose disparities were mediated
through facility-level practice variation. This suggests that

Asian women and Black women are more likely to obtain care
at facilities whose typical practices result in higher cardiac
doses independent of use of techniques like DIBH, proning, and
IMRT. These differences are large enough to drive measurable
differences in cardiac dose. Clinical judgement was used to determine tradeoffs on an individual patient basis. It remains possible that some of the disparity we observed is due to acceptable
provider- or facility-level variation in tradeoff preferences.
Nonetheless, disparities in DIBH use and other technical factors
(use of proning when DIBH not available or feasible) refute the
notion the disparities observed in our study were inevitable and
instead suggest that, in many cases, cardiac dose could have
been further reduced without compromising breast coverage.
Emphasis should therefore be placed not only on availability
and use of DIBH and proning techniques but on optimization of
planning to reduce cardiac dose regardless of which treatment
and planning techniques are employed.
In the short term, facilities may benefit from interfacility collaboration and adherence to national guidelines to facilitate uptake of discuss best practices. Indeed, MRQOC implemented
standard cardiac dose constraints in 2015, which were associated
with a statewide reduction in cardiac dose (4). However, sustainable solutions must be rooted in an understanding of why racial
disparities exist in the first place. The vast majority of individualand facility-level racial disparities are rooted in structural racism
(5). The literature is replete with studies demonstrating that facilities that serve greater numbers of racial and ethnic minoritized
patients are typically underresourced, resulting in lower-quality
care (21). These disparities are driven by racism in education,
housing, employment, and other sectors, which ultimately influence payor mix, reimbursement, and other factors that dictate
distribution of facility resources (5). They impede facilities’ bandwidth for providing modern, high-quality care, which may explain delayed uptake of technologies like DIBH. However,
structural racism may influence application of new medical
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Figure 2. Cumulative risk of death or development of at least 1 of radiation-associated ischemic events for women who received conventionally fractionated or acceler-
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research even if no new technology is required. For example, a
separate MROQC analysis demonstrated decreased use of hypofractionation among Black women (20) despite the fact that it
requires no new technology and only application of newer clinical trial data. The disparity was completely explained by decreased use of hypofractionation among facilities that treated
larger proportions of Black women. This is consistent with other
studies demonstrating that racial disparities are sometimes
explained by delayed incorporation of new research at minority
serving facilities (19). These delays may be driven by financial or
social exclusion from spaces where advances are published and
discussed, or limited time, incentives, or human capital to implement these advances (especially if they are not tied to research,
reimbursement, or productivity metrics).
In addition to its impact on institutions, structural and interpersonal racism also acts directly on patients by contributing to
disparities in baseline cardiac risk factors. For Black women,
disparities in cardiac risk factors magnified the dosimetric disparities we identified. Only 11% of Black women in the study
had no cardiac risk factors, which is deeply concerning and
speaks to the devastating impact of racism in society. To
completely eliminate disparities in cardiac toxicity after RT, solutions must address disparities in radiation technology use and
at earlier stages of the cancer continuum (including
prediagnosis).
Limitations of our study include the lack of data on Hispanic
or Latinx ethnicity, the small numbers of Asian women, and the
degree of unexplained disparity for Asian women. Collection of
race and ethnicity data must be emphasized to address these
disparities. Additionally, our data are limited to a single state.
Measuring cardiac dose disparities is challenging because these
data are not collected in cancer registries. Single institution and
clinical trial data represent alternatives but have limited generalizability to the broader population. Another limitation is that
our dose estimates of clinical significance were not biocorrected. Furthermore, the MHDs were at the lower end of the
range of doses in the study by Darby et al. (1), which may decrease the confidence in the estimates and suggest less clinical
significance. They are also based on European data, which may
not fully generalize to our population. Additional unmeasured
variables or nuances in measurement that might be missed because of grouping into categories may have affected the identification and quantification of variables mediating cardiac dose.
Finally, future efforts to expand the understanding of racial disparities in cancer outcomes should strive to collect the data
necessary to directly examine the incidence of cardiac events in
large diverse cohorts of patients treated for breast cancer, controlling also for potentially cardiotoxic and cardiopreventive
medications received, to build on the findings of the this study
focused on cardiac radiation dose.
In conclusion, we identified disparities in cardiac dose
among Asian women and Black women undergoing whole
breast RT. These disparities are primarily mediated through differences in radiation technique and facility-level practice patterns. Given that these disparities might increase the risk of
death and disability from cardiac events, solutions to address
them should be prioritized.
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